Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-term, Open Label Extension, Non-controlled Study to Assess the Efficacy and Safety of BAY 77-1931 (Lanthanum Carbonate) for Hyperphosphatemia in Patients Undergoing Hemodialysis

NCT00769496 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00769496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00769496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-term, Open Label Extension, Non-controlled Study to Assess the Efficacy and Safety of BAY 77-1931 (Lanthanum Carbonate) for Hyperphosphatemia in Patients Undergoing Hemodialysis
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2005
Completion date
May 31, 2008
Enrollment
145 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

hyperphosphatemia